Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Myasthenia Gravis – Unmet Need – Unmet Need – Generalized Myasthenia Gravis (US/EU)
Myasthenia gravis (MG) is a rare autoimmune disorder in which antibodies impair acetylcholinemediated neuromuscular transmission, causing fluctuating muscle weakness. Generalized MG (gMG) often…
Paroxysmal Nocturnal Hemoglobinuria – Unmet Need – Unmet Need – Paroxysomal Nocturnal Hemoglobinuria (US/EU)
The treatment landscape for paroxysmal nocturnal hemoglobinuria (PNH) has shifted dramatically in the past decade, moving beyond supportive care to transformative complement inhibition therapies…
Dry and Wet Age-Related Macular Degeneration – Unmet Need – Unmet Need – Wet Age-Related Macular Degeneration (US/EU)
Wet AMD (age-related macular degeneration) is a leading cause of vision loss among older adults, with significant implications on patient’s independence and quality of life. The treatment…
Crohn’s Disease – Unmet Need – Unmet Need – Moderate to Severe Crohn’s Disease (US/EU)
Crohn’s disease (CD) is a chronic inflammatory bowel disorder characterized by diarrhea, abdominal pain, and weight loss. Tumor necrosis factor (TNF)-α inhibitors, such as Johnson & Johnson…
Painful Diabetic Neuropathy – Unmet Need – Unmet Need – Painful Diabetic Neuropathy (US/EU)
Painful diabetic neuropathy (PDN) is a prevalent complication of chronic diabetes, inducing enduring and often intense pain, characterized by sensations of burning, stabbing, tingling, and…
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
